RFA-GH-21-006, Establishing the Southeast Asia Serological Surveillance Network (SASSNet) for Emergent, Endemic, and Vaccine-Preventable Infections

项目摘要 该项目旨在建立东南亚血清学监测网 （SASSNet）以及在印度尼西亚和越南的业务。该网络将应用优化和 经验证的血清学采样、分析和报告暴露于新出现和 被忽视的热带地方性传染病。项目 利用机器人ELISA和Luminex多重高通量平台， 有效和可持续地监测几十种感染/疫苗接种。抽样策略是 年龄分层匿名残余血液标本的实用方法， 印度尼西亚有25家医院，越南有20家医院。该项目加入学术 来自牛津大学印度尼西亚临床研究单位的研究合作伙伴， 越南与两国卫生部的研究人员合作。第一 一年的努力集中在SARS-CoV-2至3的血清学监测上 不同的工作流程：1）通过ELISA建立常规的国家血清学监测; 2） 在选定的地点进行SARS-CoV暴露的横截面调查;以及3）以下两项 在1年期间通过ELISA进行血清学评估的纵向队列，其中 在一个队列中，在SARS-CoV-2 qPCR阳性后立即入组， 另一种是在接种COVID-19疫苗后立即接种。第一年还将看到优化 和验证用于六种不同SARS-CoV-2抗原靶标的多重Luminex测定， 三种不同的免疫球蛋白（A、M和G），沿着Spike S1和Spike N蛋白， MERS-CoV和四种季节性冠状病毒。相同的多重检测将在以后包括 8种新出现的感染（如尼帕病毒、寨卡病毒和日本脑炎病毒），被忽视 热带感染（例如，登革热、疟疾、丝虫病、麻风病和肠道蠕虫病）， 和疫苗可预防的感染（如麻疹、白喉和破伤风）。多路复用器 血清学检测将构成国家例行血清学监测的基础， 该项目旨在建设印度尼西亚卫生部设施的能力， 越南，并在5- 10年期结束时将这些设施移交给有关当局。 项目的年寿命。

Project Summary The project aims to establish the Southeast Asian Serological Surveillance Network (SASSNet) and operations in Indonesia and Viet Nam. The Network will apply optimized and validated serological sampling, analysis, and reporting of exposures to emerging and endemic neglected tropical infectious diseases of regional importance. The project leverages both robotic ELISA and Luminex multiplex high throughput platforms in order to efficiently and sustainably surveil several dozen infections/vaccinations. Sampling strategy is the pragmatic approach of age-stratified anonymized residual blood specimens from networks of 25 hospitals in Indonesia and 20 in Viet Nam. The project joins academic research partners from the University of Oxford’s clinical research units in Indonesia and Viet Nam with researchers within the respective Ministry of Health in both nations. The first year of effort focuses exclusively on serological surveillance of SARS-CoV-2 through 3 distinct workstreams: 1) establishing routine national serological surveillance by ELISA; 2) cross-sectional surveys for exposure to SARS-CoV at selected sites; and 3) following two longitudinal cohorts for serological assessment by ELISA over a 1-year period, where enrollment in one cohort immediately follows qPCR positivity for SARS-CoV-2, and in the other immediately follows vaccination against COVID-19. Year 1 will also see the optimizing and validation of a multiplex Luminex assay for six distinct SARS-CoV-2 antigenic targets and three distinct immunoglobulins (A, M, and G), along with Spike S1 and Spike N proteins of MERS-CoV, and four seasonal coronaviruses. The same multiplex assay will later include eight emerging infections (e.g. Nipah, Zika, and Japanese encephalitis viruses), neglected tropical infections (e.g., Dengue, malaria, filariasis, leprosy, and intestinal helminthiases), and vaccine-preventable infections (e.g. measles, diphtheria, and tetanus). That multiplex serological assay will constitute the basis of routine national serological surveillance, and the project aims to build that capacity within Ministry of Health facilities in Indonesia and Viet Nam, and to turn those facilities over to the respective authorities at the end of the 5- year life of the project.